Free Trial

LB Pharmaceuticals (LBRX) Stock Forecast & Price Target

LB Pharmaceuticals logo
$36.74 +0.05 (+0.14%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$36.76 +0.02 (+0.05%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LB Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
1
Buy
10

Based on 13 Wall Street analysts who have issued ratings for LB Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 2 have given a sell rating, 1 has given a hold rating, and 10 have given a buy rating for LBRX.

Consensus Price Target

$57.40
56.23% Upside
According to the 13 analysts' twelve-month price targets for LB Pharmaceuticals, the average price target is $57.40. The highest price target for LBRX is $80.00, while the lowest price target for LBRX is $35.00. The average price target represents a forecasted upside of 56.23% from the current price of $36.74.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for LBRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for LB Pharmaceuticals and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LBRX Analyst Ratings Over Time

TypeCurrent Forecast
10/17/25 to 10/17/26
1 Month Ago
9/17/25 to 9/17/26
3 Months Ago
7/19/25 to 7/19/26
1 Year Ago
10/17/24 to 10/17/25
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
10 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$57.40$49.63$39.50$30.50
Forecasted Upside56.23% Upside17.76% Upside25.76% Upside95.51% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

LBRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LBRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

LB Pharmaceuticals Stock vs. The Competition

TypeLB PharmaceuticalsHealthcare CompaniesBroader Market
Consensus Rating Score
2.62
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside56.23% Upside1,213.35% Upside18.02% Upside
News Sentiment Rating
Positive News

See Recent LBRX News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/12/2026
HC Wainwright logo
HC Wainwright
4 of 5 stars
Raghuram Selvaraju
5 of 5 stars
Reiterated RatingBuy
10/12/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Delma Caiati
Delma Caiati
Not Rated
Reiterated RatingBuy
10/12/2026 UpgradeBuy
10/12/2026 DowngradeHold ➝ Strong Sell
10/9/2026Initiated CoverageBuy$65.00+87.81%
10/5/2026DowngradeBuy ➝ Neutral$37.00 ➝ $35.00-5.38%
10/2/2026Initiated CoverageBuy$68.00+82.40%
8/13/2026Set Target$53.00+18.12%
8/12/2026Boost TargetOutperform$46.00 ➝ $54.00+19.13%
8/11/2026 DowngradeSell (D+) ➝ Sell (D)
8/3/2026 Reiterated RatingOverweight$78.00+81.12%
7/7/2026Initiated CoverageOutperform$45.00+34.69%
4/10/2026Initiated CoverageBuy$36.00+36.93%
10/6/2025 UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:15 AM ET.


LBRX Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for LB Pharmaceuticals is $57.40, with a high forecast of $80.00 and a low forecast of $35.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LB Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LBRX shares.

According to analysts, LB Pharmaceuticals's stock has a predicted upside of 56.23% based on their 12-month stock forecasts.

Over the previous 90 days, LB Pharmaceuticals's stock had 3 upgrades and 3 downgrades by analysts.

Analysts like LB Pharmaceuticals more than other "healthcare" companies. The consensus rating for LB Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how LBRX compares to other companies.


MarketBeat monitors more than a dozen sources for LB Pharmaceuticals analyst ratings, with the most recent rating issued on 10/12/2026.
From Our Partners